Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.58 |
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479456 | 1.00 | ADRB3 (0.58) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL6490053 | 0.94 | ADRB3 (0.53) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL6490059 | 0.94 | ADRB3 (0.53) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL7687077 | 0.93 | ADRB3 (0.52) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL7687080 | 0.93 | ADRB3 (0.52) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL7689875 | 0.92 | ADRB3 (0.52) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL7693483 | 0.91 | ADRB3 (0.57) | ADRB3ADRB1METADRB2 | |
| SCHEMBL7692899 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL7692667 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1METAXLMERTK | |
| SCHEMBL6478782 | 0.91 | ADRB3 (0.51) | ADRB3ADRB1METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885MET 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.